Allergan PLC. (AGN) Given Average Rating of “Buy” by Analysts
Shares of Allergan PLC. (NYSE:AGN) have been given an average rating of “Buy” by the twenty-three research firms that are currently covering the stock, Marketbeat.com reports. Eight analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $274.47.
A number of research firms have recently weighed in on AGN. BidaskClub cut Allergan PLC. from a “buy” rating to a “hold” rating in a report on Wednesday. Citigroup Inc. reaffirmed a “focus list” rating and set a $261.27 price target (up previously from $184.50) on shares of Allergan PLC. in a report on Friday, April 21st. Deutsche Bank AG reissued a “buy” rating and set a $273.00 target price (up previously from $265.00) on shares of Allergan PLC. in a report on Monday, July 17th. Goldman Sachs Group, Inc. (The) cut Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 target price on the stock. in a report on Wednesday, May 10th. Finally, Royal Bank Of Canada boosted their target price on Allergan PLC. from $279.00 to $284.00 and gave the stock an “outperform” rating in a report on Wednesday, May 10th.
In other news, Director Nesli Basgoz sold 1,889 shares of the business’s stock in a transaction on Thursday, May 18th. The shares were sold at an average price of $220.45, for a total transaction of $416,430.05. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.36% of the company’s stock.
Large investors have recently added to or reduced their stakes in the stock. National Investment Services Inc. WI acquired a new stake in Allergan PLC. during the first quarter valued at about $1,731,000. Portland Global Advisors LLC raised its position in Allergan PLC. by 3.0% in the first quarter. Portland Global Advisors LLC now owns 7,581 shares of the company’s stock worth $1,811,000 after buying an additional 223 shares in the last quarter. Howe & Rusling Inc. raised its position in Allergan PLC. by 41.7% in the first quarter. Howe & Rusling Inc. now owns 17,507 shares of the company’s stock worth $4,183,000 after buying an additional 5,149 shares in the last quarter. Addison Capital Co raised its position in Allergan PLC. by 1.9% in the first quarter. Addison Capital Co now owns 10,242 shares of the company’s stock worth $2,447,000 after buying an additional 192 shares in the last quarter. Finally, Oliver Luxxe Assets LLC purchased a new position in Allergan PLC. during the first quarter worth $2,939,000. 84.77% of the stock is owned by institutional investors and hedge funds.
Shares of Allergan PLC. (NYSE AGN) opened at 232.88 on Friday. The firm’s 50-day moving average price is $245.93 and its 200 day moving average price is $238.13. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80. The stock has a market capitalization of $78.06 billion, a P/E ratio of 7.10 and a beta of 1.16.
Allergan PLC. (NYSE:AGN) last issued its earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, beating the Zacks’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.25% and a net margin of 79.17%. The company had revenue of $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. During the same period in the previous year, the firm posted $3.35 earnings per share. Allergan PLC.’s quarterly revenue was up 8.8% compared to the same quarter last year. Analysts expect that Allergan PLC. will post $16.27 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be issued a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a dividend yield of 1.20%. The ex-dividend date of this dividend is Wednesday, August 16th. Allergan PLC.’s dividend payout ratio is currently 9.95%.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.